Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Paxmedica Inc (PXMD)

Paxmedica Inc (PXMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,053
  • Shares Outstanding, K 7,466
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,290 K
  • 60-Month Beta -0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.81
Trade PXMD with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -14.38
  • Most Recent Earnings $-5.20 on 11/15/23
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.43
  • Number of Estimates 1
  • High Estimate -0.43
  • Low Estimate -0.43
  • Prior Year -5.10
  • Growth Rate Est. (year over year) +91.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2500 +5.60%
on 05/07/24
1.1900 -77.82%
on 04/12/24
-0.2260 (-46.12%)
since 04/05/24
3-Month
0.2500 +5.60%
on 05/07/24
1.1900 -77.82%
on 04/12/24
-0.1940 (-42.36%)
since 02/07/24
52-Week
0.2500 +5.60%
on 05/07/24
29.7500 -99.11%
on 05/15/23
-25.0660 (-98.96%)
since 05/05/23

Most Recent Stories

More News
PaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently announced that it has completed its three registration/validation batches of PAX-101,...

PXMD : 0.2640 (-4.00%)
PaxMedica (NASDAQ: PXMD) Featured in Latest Bell2Bell Podcast Release

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, was featured in the latest episode of The Bell2Bell Podcast as part of IBN’s...

PXMD : 0.2640 (-4.00%)
Urgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in Malawi

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation...

PXMD : 0.2640 (-4.00%)
PaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has made a key announcement regarding the development of its proprietary PAX-101, an IV...

PXMD : 0.2640 (-4.00%)
PaxMedica (NASDAQ: PXMD) Responding to Emergency Request for IV Suramin from African Health Ministry

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has received an urgent request from the Ministry of Health (“MOH”) of Malawi requesting...

PXMD : 0.2640 (-4.00%)
PaxMedica (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has completed the execution of three pivotal registration/validation batches of PAX-101,...

PXMD : 0.2640 (-4.00%)
PaxMedica (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Conditions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”)...

PXMD : 0.2640 (-4.00%)
PaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more...

PXMD : 0.2640 (-4.00%)
PaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder...

PXMD : 0.2640 (-4.00%)
PaxMedica (NASDAQ: PXMD) Shares Innovations in ASD Treatments in Updated Presentation

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview...

PXMD : 0.2640 (-4.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

PaxMedica Inc., a Phase 2 biotech developing therapies for neurodevelopmental disorders. PaxMedica Inc. is based in Tarrytown, New York.

See More

Key Turning Points

3rd Resistance Point 0.4103
2nd Resistance Point 0.3777
1st Resistance Point 0.3263
Last Price 0.2640
1st Support Level 0.2423
2nd Support Level 0.2097
3rd Support Level 0.1583

See More

52-Week High 29.7500
Fibonacci 61.8% 18.4810
Fibonacci 50% 15.0000
Fibonacci 38.2% 11.5190
Last Price 0.2640
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar